Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9684530 | 0.91 | MEN1 (0.47) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL22528291 | 0.88 | CYP3A4 (0.50) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL28035382 | 0.83 | EPHX1 (0.45) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL28932747 | 0.83 | EPHX1 (0.45) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL11418769 | 0.82 | S1PR2 (0.47) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL23969048 | 0.81 | MEN1 (0.50) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL13575613 | 0.81 | MEN1 (0.53) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL13575612 | 0.78 | PPARD (0.45) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL28676330 | 0.78 | MEN1 (0.44) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL13387096 | 0.78 | LPAR3 (0.52) | LPAR3LPAR1LPAR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2024-08-01 | — | — | US | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3595633-B1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230038716-A1 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | DFB SORIA, LLC | 2023-02-09 | — | — | US | disclosed |
| EP-1680223-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | Fqubed, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005012549-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | FQUBED, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040023841-A1 | Combinatorial method for rapid screening of drug delivery formulations | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-02-05 | — | — | US | disclosed |
| EP-1105088-A4 | PERSONAL CLEANSING COMPOSITIONS HAVING PHOTOPROTECTIVE AGENTS | SKINNOVATIVE DERMATOLOGIC CONC (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002016941-A2 | A COMBINATORIAL METHOD FOR RAPID SCREENING OF DRUG DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-1105088-A1 | PERSONAL CLEANSING COMPOSITIONS HAVING PHOTOPROTECTIVE AGENTS | Skinnovative Dermatologic Concepts, L.L.C. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6217852-B1 | APPLYING DURING WASHING; SUNSCREEN AGENT | SKINNOVATIVE DERMATOLOGIC CONCEPTS, L.L.C. | 2001-04-17 | — | — | US | disclosed |
| WO-2000009081-A1 | PERSONAL CLEANSING COMPOSITIONS HAVING PHOTOPROTECTIVE AGENTS | SKINNOVATIVE DERMATOLOGIC CONCEPTS, L.L.C. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | MEN1 1285/4885GAA 2948/4885CYP2C9 4676/4885 |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | MEN1 1571/4885GAA 2752/4885CYP2C9 4825/4885 |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | KRT18, TUBB3, TUBA3E | MEN1 1701/4885GAA 3188/4885CYP2C9 4023/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | MEN1 1571/4885GAA 2752/4885CYP2C9 4825/4885 |
| US-20230038716-A1 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | NCL, HUNK, LMNB1 | MEN1 780/4885GAA 1811/4885CYP2C9 4548/4885 |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | MEN1 1285/4885GAA 2948/4885CYP2C9 4676/4885 |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | MEN1 1285/4885GAA 2948/4885CYP2C9 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.